Faricimab for treatment-resistant choroidal neovascularization (CNV) in neovascular age-related macular degeneration (nAMD): seven-months results using artificial intelligence and OCTA

Faricimab for treatment-resistant choroidal neovascularization (CNV) in neovascular age-related macular degeneration (nAMD): seven-months results using artificial intelligence and OCTA

Abstract Background To analyze the therapeutic response to faricimab 6 mg/0.05 ml in eyes with neovascular AMD (nAMD) with refractory intra- and/or subretinal fluid due to choroidal neovascularization (CNV), previously unresponsive to 4 mg monthly aflibercept and combination therapy with anti-VEGF a...

Full description

Saved in:
Bibliographic Details
Main Authors: Anna Heinke, Alexandra Warter, Ines D. Nagel, Akshay Agnihotri, Nehal Nailesh Mehta, Carlo Miguel B. Galang, Daniel N. Deussen, Dirk-Uwe G. Bartsch, Lingyun Cheng, Henry A. Ferreyra, William R. Freeman
Format: Article
Language:English
Published: BMC 2025-06-01
Series:International Journal of Retina and Vitreous
Subjects:
ANG-2 (Angiopoietin 2)
Anti-VEGF (Anti- Vascular Endothelial Growth Factor)
Faricimab (VABYSMO) or faricimab-svoa
Intraretinal fluid (IRF)
Subretinal fluid (SRF)
PED (Pigment Epithelium Detachment)
Online Access:https://doi.org/10.1186/s40942-025-00691-4
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://doi.org/10.1186/s40942-025-00691-4

Similar Items